On Tuesday, Regeneron Prescription drugs Inc REGN reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29.
The corporate reported gross sales of $3.79 billion, up 10%, beating the consensus of $3.75 billion.
“Regeneron’s monetary and business energy permits for continued funding in our industry-leading R&D pipeline, whereas concurrently returning capital to our shareholders by way of our newly initiated dividend program and elevated share repurchase capability,” mentioned Leonard S. Schleifer, Board co-Chair, President and CEO of Regeneron.
“In 2025, we are going to proceed to concentrate on our 4 blockbuster medicines as we progress our roughly 40 investigational candidates protecting dozens of illness states with expansive market potential.”
Additionally Learn: Regeneron Pipeline Goals To Deal with $220 Billion Therapeutic Alternatives By 2030
Fourth quarter 2024 U.S. web gross sales for Eylea HD and Eylea elevated 2% year-over-year to $1.49 billion, together with $305 million from Eylea HD.
A decrease web promoting value impacted the online product gross sales of Eylea HD and Eylea within the fourth quarter and full yr 2024 in comparison with the identical intervals of 2023. LLibtayo’s world web gross sales elevated by 50% to $367 million.
Sanofi collaboration income elevated within the fourth quarter and full yr 2024, in comparison with the identical intervals of 2023, attributable to a rise within the firm’s share of earnings from the commercialization of antibodies, which have been $1.043 billion and $886 million within the fourth quarter of 2024 and 2023, respectively, and $3.924 billion and $3.137 billion for full-year 2024 and 2023, respectively.
Dividend: Regeneron accepted initiating a quarterly money dividend program and declared a money dividend of $0.88 per share, payable on March 20, 2025, to shareholders of report as of February 20, 2025.
The corporate intends to pay a money dividend each quarter.
The corporate’s board of administrators additionally licensed a further $3.0 billion share repurchase program, bringing the present capability to roughly $4.5 billion.
Worth Motion: REGN inventory is up 5.23% at $701.72 ultimately test Tuesday.
Learn Subsequent:
Photograph by way of Firm
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
